Stephan Kowalyk, MD
Endocrinology, Diabetes & Metabolism · Greensburg, PANPI 1457458168
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $478,448 of the $590,966 with a category attached, or 81.0%. 60 manufacturers reported payments, led by Novo Nordisk at 30.1% of the total. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,624 payments — averaging $225.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$178K
- Lilly USA, LLC$119K
- Sanofi-aventis U.S. LLC$70K
- AstraZeneca$55K
- Dexcom, Inc.$40K
- Boehringer Ingelheim$26K
- plus $103K from 54 others
Across 18 payments — averaging $1969.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$24K
- Lexicon Pharmaceuticals, Inc.$12K
What the payments were for
- Consulting fees$9,9182%
- Speaking & faculty fees$478,44881%
- Travel & lodging$58,24810%
- Food & beverage$44,1087%
- Education$1360%
- Gifts$590%
- Other$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$76,921
- RYBELSUS$75,626
- Ozempic$71,788
- FARXIGA$52,224
- JARDIANCE$39,510
- SOLIQUA 100/33$39,051
- DEXCOM G7 GSS (161)$38,158
- TOUJEO$29,588
- Kerendia$24,040
- DEXCOM STELO GLUCOSE BIOSENSOR$17,834
- V-GO$17,610
- FREESTYLE LIBRE 3$13,136
- INVOKANA$11,700
- Tresiba$11,318
- CeQur Simplicity$8,639
- AFREZZA$5,719
- Victoza$3,959
- GVOKE HYPOPEN$2,415
- Minimed 670G System$1,438
- V-GO DISPOSABLE INSULIN DELIVERY$1,200
How this compares
$590,966 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,983 | $2,294,737 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 1,020 | $1,063,514 |
| JardianceEmpagliflozin | 902 | $843,677 |
| MounjaroTirzepatide | 492 | $569,386 |
| TrulicityDulaglutide | 333 | $352,785 |
| FarxigaDapagliflozin Propanediol | 382 | $312,619 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 148 | $228,631 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 295 | $200,397 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 100 | $157,203 |
| TradjentaLinagliptin | 260 | $157,177 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 188 | $144,904 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 82 | $120,786 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 769 | $100,202 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 185 | $91,038 |
| Humalog Kwikpen U-100Insulin Lispro | 341 | $86,988 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Novolog, Rybelsus | $178,040 | $2,649,4802,455 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy, Glyxambi, Synjardy Xr | $25,563 | $1,193,8931,390 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $70,025 | $1,063,5141,020 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Lyumjev | $119,403 | $1,006,3871,105 claims |
| AstraZenecaFarxiga | $54,633 | $312,619382 claims |
| MerckJanuvia | $492 | $75,20776 claims |
| Johnson & JohnsonInvokana | $12,484 | $64,25152 claims |
| Mannkind CorporationAfrezza | $12,737 | $31,97019 claims |
| AbbVieSynthroid | $613 | $24,777452 claims |
| BayerKerendia | $25,077 | $24,75321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Greensburg
- Serge JabbourPhiladelphia$1.2M
- Vijay BahlPittsburgh$998K
- Geraldo SaavedraWhitehall$698K
- Jane MayrinPhiladelphia$628K
- Matthew KaneWest Chester$577K
- Intekhab AhmedPhiladelphia$528K
- Swarna VarmaPittsburgh$520K
- James DickeHanover$425K
- Mitchell LazarPhiladelphia$358K
- Vishal DattaCollegeville$334K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.